Penpulimab plus chemotherapy significantly improved progression-free survival in recurrent or metastatic nasopharyngeal carcinoma
New drug plus chemo delays cancer growth in advanced nasopharyngeal cases
This randomized, double-blind phase 3 trial evaluated penpulimab combined with cisplatin/carboplatin and gemcitabine versus placebo plus che…
Adding penpulimab to chemotherapy delays cancer growth by nearly three months in advanced nasopharyngeal cases, offering new hope for patien…
Becotatug vedotin shows antitumor activity in pretreated recurrent or metastatic nasopharyngeal carcinoma
A New Drug Shows Promise for Tough-to-Treat Nasopharyngeal Cancer
A phase IIa single-arm trial of 61 patients with platinum-refractory recurrent or metastatic nasopharyngeal carcinoma found an objective res…
For patients with a hard-to-treat head and neck cancer who have few treatments left, a new experimental therapy is showing encouraging resul…
Research across Head and Neck Cancer
Related studies from across the Head and Neck Cancer family.
Primary endoscopic nasopharyngectomy achieves 90.6% five-year overall survival across all tumor stages in nasopharyngeal carcinoma
Endoscopic Surgery Shows Promise for Early Stage Nasopharyngeal Cancer
This systematic review and meta-analysis of 164 patients found that primary endoscopic nasopharyngectomy (pENPG) achieved a 90.6% five-year …
A review of surgical outcomes suggests endoscopic surgery may offer a way to treat early-stage nasopharyngeal cancer while reducing radiatio…
Anti-PD-1 based chemo-immunotherapy for nasopharyngeal carcinoma yields objective response rates of 20 to 91 percent
New Research Explores Treatments for Nasopharyngeal Carcinoma
This narrative synthesis reviews 182 studies regarding the mechanisms and treatments for nasopharyngeal carcinoma. It highlights that anti-P…
New research explores how immunotherapy and targeted treatments can improve outcomes for patients with nasopharyngeal carcinoma.
PD-1 inhibitors plus chemotherapy achieve 64% objective response rate in recurrent or metastatic nasopharyngeal carcinoma
Different PD-1 Inhibitors Show Varying Results for Nasopharyngeal Cancer
This systematic review and meta-analysis of 1,459 patients with recurrent or metastatic nasopharyngeal carcinoma found a pooled objective re…
A review of 1,459 patients shows that different PD-1 inhibitors combined with chemotherapy offer varying survival and response rates for nas…
Immune checkpoint blockade shows promise but faces resistance challenges in nasopharyngeal carcinoma
Immune checkpoint blockade may help treat nasopharyngeal carcinoma
This narrative review examines immune checkpoint blockade in nasopharyngeal carcinoma. It highlights that while 5-year overall survival for …
A narrative review suggests immune checkpoint blockade could guide new treatments for nasopharyngeal carcinoma, though resistance remains a …
Review of epigenetic dysregulation in nasopharyngeal carcinoma management
Epigenetic changes could guide better treatment plans for nasopharyngeal cancer patients soon
This narrative review examines epigenetic dysregulation, including aberrant DNA and RNA methylation, histone modifications, and non-coding R…
A new review explains how silent chemical switches control cancer spread and how doctors might use them to tailor treatments for patients.
Comprehensive salivary gland–sparing helical tomotherapy reduces radiation-induced xerostomia in nasopharyngeal carcinoma patients
New radiation technique spares saliva glands in throat cancer
This prospective cohort study evaluated 266 patients with nasopharyngeal carcinoma treated with comprehensive salivary gland–sparing helical…
A precise radiation method cut severe dry mouth to 0.4% in nasopharyngeal cancer patients, while keeping survival high.
EBNA1 SeroStrip-HT shows high accuracy for nasopharyngeal carcinoma risk assessment in a nested case-control study
A Blood Test May Spot a Rare Cancer Years Before Symptoms Appear
This nested case-control study evaluated the EBNA1 SeroStrip-HT in prospective cohorts from Singapore and Shanghai, China.
A simple blood test can spot a rare throat cancer up to four years before symptoms appear, giving doctors time to treat it early.
Meta-analysis of 7,750 saliva samples validates non-invasive disease prediction models for nasopharyngeal carcinoma, colorectal cancer, and PLHIV
Spit Test Could Predict Multiple Diseases
This meta-analysis reviewed public 16S saliva data from 22 cohorts involving 7,750 samples to assess multi-disease prediction models.
A simple spit test might soon predict multiple diseases at once, offering a non-invasive way to check for serious health conditions without …
Mini review examines genetic polymorphisms and viral markers linked to nasopharyngeal carcinoma risk
What genes and viruses really drive this rare throat cancer risk?
This mini review synthesizes evidence regarding genetic polymorphisms and viral markers associated with nasopharyngeal carcinoma susceptibil…
A rare throat cancer is driven by specific gene changes and the Epstein-Barr virus, while common HPV links remain unproven for this disease.
Intravenous vitamin C did not reduce gastrointestinal toxicities but attenuated platelet decline in nasopharyngeal carcinoma patients
Intravenous vitamin C may help protect platelets during cancer treatment in Thailand
A randomized, double-blind, placebo-controlled trial in Thailand assessed 2 g of intravenous vitamin C prior to chemotherapy in patients wit…
Intravenous vitamin C helped slow platelet loss in Thai cancer patients undergoing treatment, though it did not reduce common side effects l…
Anti-PD-1 plus chemoradiotherapy improved event-free survival in MS1 subtype nasopharyngeal carcinoma patients compared with chemoradiotherapy alone
New Test Picks Who Wins From Cancer Drug
This review analyzed pooled data from two Phase III randomized clinical trials involving 407 patients with locoregionally advanced nasophary…
A new test identifies which nasopharyngeal cancer patients will survive longer when adding immunotherapy to standard radiation and chemother…
MRLN sparing radiotherapy shows non-inferior survival, reduced toxicity in nasopharyngeal carcinoma
New Radiation Plan Saves Swallowing Power
A phase 3 RCT of 568 adults with untreated, non-metastatic nasopharyngeal carcinoma found MRLN sparing radiotherapy was non-inferior to stan…
A new radiation plan for throat cancer lets patients skip a specific area, helping them keep their swallowing strength and eat normally for …